Li, Y., Chen, X., He, W., Xia, S., Jiang, X., Li, X., Bai, J., Li, N., Chen, L., & Yang, B. (2020). Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells. Nutrition and Cancer, 0(0), 1–9. https://doi.org/10.1080/01635581.2020.1802494Cite
Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration with AstraZeneca to evaluate the combination of patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate, and TAGRISSO, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in Phase I clinical development for non-small cell lung cancer and TNBC.
Roche announced that the European Commission has granted conditional marketing authorisation for Rozlytrek® for the treatment of adult and paediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options.
miRNA microarray analysis showed that miR-4634 levels in A549 cells increased significantly after everolimus treatment. Decreased expression of miR-4634 was also found in non-small-cell lung carcinoma cell lines and patients’ tumors by qPCR.
Researchers showed that miR-135a was aberrantly downregulated in non-small cell lung cancer (NSCLC) cells in comparison with normal bronchial epithelial cells, and the expression of miR-135a inhibited proliferation, invasion and metastasis of NSCLC cells in vitro.
Zhang, M., Lin, B., Liu, Y., Huang, T., Chen, M., Lian, D., Deng, S., & Zhuang, C. (2020). LINC00324 affects non-small cell lung cancer cell proliferation and invasion through regulation of the miR-139-5p/IGF1R axis. Molecular and Cellular Biochemistry. https://doi.org/10.1007/s11010-020-03819-2Cite
Two cisplatin-resistant non-small cell lung cancer cell lines were established by gradually increasing concentrations of cisplatin in the media. The resulting cell lines possessed high resistance to cisplatin and strong proliferation, migration, and colony formation abilities compared to the parental cells.
Investigators showed the tumor-promoting function of a cell cycle-related protein, PIERCE1, in KRAS-mutant non-small cell lung cancer. Mechanistically, PIERCE1 depletion inhibited cell growth and AKT phosphorylation at S473, which was particularly observed in KRAS-mutant lung cancers.
The authors investigated the role of NRF2 in resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). They showed that NRF2 protein levels were markedly increased in a panel of EGFR-TKI-resistant non-small cell lung cancer cell lines due to slow degradation of NRF2 protein.